Aclaris Therapeutics
ACRS
99 hedge funds and large institutions have $289M invested in Aclaris Therapeutics in 2018 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 20 reducing their positions, and 11 closing their positions.
1,657% more call options, than puts
Call options by funds: $123K | Put options by funds: $7K
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
115% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 20
15% more funds holding
Funds holding: 86 → 99 (+13)
0.28% less ownership
Funds ownership: 95.74% → 95.46% (-0.28%)
33% less capital invested
Capital invested by funds: $431M → $289M (-$142M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$28.9M |
| 2 |
BC
Broadfin Capital
New York
|
+$19.4M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$13.6M |
| 4 |
BlackRock
New York
|
+$11.4M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$21M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.57M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$7.9M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$5.53M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.83M |
ACRS Hedge Fund Activity: Q4 2018 in Review
99 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2018, worth a combined $289M — down 33% from $431M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ACRS positions and 11 closed out — a net gain of 13 holders — while 43 added to existing stakes and 20 trimmed.
The largest buyer was Deerfield Management, adding an estimated $28.9M. The largest seller was Polar Capital, exiting entirely with an estimated $21M sold.
- 99 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2018, up from 86 in Q3 2018.
- Funds reported $289M of Aclaris Therapeutics stock for Q4 2018, down 33% quarter-over-quarter.
- 24 funds opened new Aclaris Therapeutics positions in Q4 2018 and 11 closed out, a net change of +13 holders.
- The largest Aclaris Therapeutics buyer in Q4 2018 was Deerfield Management, an estimated $28.9M added.
- The largest Aclaris Therapeutics seller in Q4 2018 was Polar Capital, an estimated $21M sold.
Based on aggregated 13F filings for Q4 2018.